| EBITDA Margin: guided vs achieved | 5.00% achieved Guided 5.00%; confirmed by management |
|---|---|
| Management target | Revenue 23.0% FY27 |
| Revenue growth | 38.2% YoY growth, driven by 19.6% organic and 20.4% inorganic gains. |
|---|---|
| Margins | Structural expansion; EBITDA margin hit 5% due to scale and MedTech. |
| Demand visibility | Strong; IPM growing double digits led by volume across all therapy areas. |
| Management confidence | High; confident in organic scalability and achieving full-year targets early. |
Growth
Revenue grew 40% on a like-for-like basis; organic growth was 19.6% while inorganic contributions from past acquisitions added 20.4%.
Outlook
Management maintains FY27 revenue growth guidance of 23% excluding new acquisitions and a 50% EBITDA-to-operating cash flow conversion target.
Risks
High reliance on past M&A for growth; significant minority interest leakage (27% of profit) via non-wholly owned subsidiaries.
Last quarter's promises, checked
Delivered
- Guided 30% LFL Revenue Growth → delivered 31.5% (= BEAT)
- Guided 4% EBITDA Margin → delivered 4% (= BEAT)
- Guided 50% EBITDA-to-OCF conversion → delivered 104.6cr OCF on 86cr Q4 EBITDA (= BEAT)
Partly delivered
- Guided 25-27% Minority Interest leakage → delivered 27% in current Q1 (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: ENTERO. Summary written with AI assistance from the document.
Entero Healthcare Solutions Ltd: key numbers
- Share price
- ₹1,821.80
- Market cap
- ₹7,929 Cr
- Revenue (annual)
- ₹6,591 Cr
- Net profit (annual)
- ₹115.0 Cr
- P/E (TTM)
- 63.2×Sector 57.8×
- Promoter holding
- 52.40%-0.02% QoQ
- FII holding
- 4.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Entero Healthcare Solutions Ltd
All →Entero Healthcare Solutions Capital Structure Change
Surbhi Singh (Prasid Uno Family Trust), a non-promoter, sold 21.30 lakh Entero Healthcare shares via bulk/block deals. Stake fell from 7.94% to 3.05%; no transaction value disclosed.
Entero Healthcare Solutions Legal & Regulatory
Entero Healthcare Solutions reported a GST penalty of Rs. 0.13 Crore imposed on its subsidiary, ACE Cardiopathy Solutions, for non-generation of an E-Invoice.
- Value
- ₹0.13 Cr
Entero Healthcare Solutions Other Announcement
Entero Healthcare Solutions Ltd filed its quarterly shareholding pattern for the period ended March 31, 2026, as per regulatory requirements.
Entero Healthcare Solutions Investor Presentation: Key Takeaways
Q1FY27 revenue grew 38.2% YoY to ₹1,940.5 Cr with significant margin expansion. Strategy focuses on MedTech scaling and consolidating India's fragmented pharmaceutical distribution market.
Entero Healthcare Solutions Q1 FY27 Results: Net Profit ₹52.1 Cr, Up 72.5% YoY
Entero Healthcare Solutions Ltd reported revenue from operations of ₹1,940 Cr (+38.2% YoY) and net profit of ₹52.1 Cr (+72.5% YoY) for Q1 FY27.
- Key figure
- Net profit ₹52.1 Cr · +72.5% YoY
Entero Healthcare Solutions Earnings Call: Key Takeaways
Entero delivered solid FY26 results, meeting all guidance parameters. Management transitions focus toward organic growth and margin expansion through technology-led scaling and higher-margin MedTech distribution.